Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

ClinicalTrials.gov ID: NCT05090904

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05090904. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 12:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.

Study identification

NCT ID
NCT05090904
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Insmed Incorporated
Industry
Enrollment
29 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2021 (Actual)
Primary completion
Nov 1, 2022 (Actual)
Completion
Nov 1, 2022 (Actual)
Last update posted
Mar 12, 2026

2021 – 2022

United States locations

U.S. sites
14
U.S. states
12
U.S. cities
13
Facility City State ZIP Site status
USA001 Gainesville Florida 32610 —
USA016 Augusta Georgia 30912 —
USA025 Glenview Illinois 60025 —
USA011 Boston Massachusetts 02115 —
USA023 Ann Arbor Michigan 48109 —
USA002 St Louis Missouri 63101 —
USA022 New York New York 10032 —
USA008 Cleveland Ohio 44106 —
USA006 Cleveland Ohio 44195 —
USA018 Portland Oregon 97239 —
USA009 Charleston South Carolina 29425 —
USA017 Nashville Tennessee 37232 —
USA004 Dallas Texas 75390 —
USA003 Tyler Texas 75708 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05090904, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 12, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.